Back HIV/AIDS

HIV / AIDS

Top 10 HIV and Hepatitis Stories of 2016

Simplification and optimization of antiretroviral therapy for HIV, wider use of pre-exposure prophylaxis (PrEP), a growing appreciation that people with undetectable viral load do not transmit HIV, and an expanded armamentarium of treatments for hepatitis C were among the top HIV and viral hepatitis headlines this year. Here's a look back at some of our biggest news from 2016.

alt

Dolutegravir + Rilpivirine HIV Maintenance Regimen Looks Good in Phase 3 Studies

Switching to a 2-drug regimen of dolutegravir plus rilpivirine maintained viral suppression among people on successful 3- or 4-drug antiretroviral therapy (ART) in a pair of Phase 3 clinical trials, according to an announcement last week from ViiV Healthcare.

alt

1. HIV Undetectable = Uninfectious

Evidence continues to accumulate showing that HIV-positive people on effective combination antiretroviral therapy (ART) with a consistently undetectable viral load have a very low -- perhaps as low as zero -- risk of transmitting the virus.

alt

U.K.'s Largest Sexual Health Clinic Saw 40% Drop in New HIV Diagnoses in 2016

The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the U.K., saw an unprecedented 40% drop in new HIV diagnoses this year. Another clinic, the Mortimer Market Centre a mile away from Dean Street, has seen an even bigger 50% fall.

alt

2. Quicker, Simpler, and Better Antiretroviral Therapy

Modern antiretroviral therapy (ART) is highly effective and well-tolerated, but researchers continue to refine, streamline, and optimize treatment strategies. Studies presented this year show the benefits of starting ART as soon as possible after HIV diagnosis and suggest that fewer drugs taken less often may be effective for many people.

alt

First Large Study of Long-Acting Injectable for HIV Prevention Now Underway

The National Institutes of Health and industry collaborators last week launched a large-scale clinical trial to test long-acting injectable cabotegravir for HIV prevention. Study HPTN 083 will compare cabotegravir injections administered every 8 weeks versus once-daily oral tenofovir/emtricitabine (Truvada) pre-exposure prophylaxis (PrEP). Results are expected in 2021.

alt

3. Renewed Focus on HIV Vaccines and Antibodies

Researchers intensified the search for novel types of therapies to prevent, treat, and potentially cure HIV, including immune-based strategies such as antibodies and vaccines.

alt